Leerink Partnrs Issues Positive Forecast for BEAM Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Leerink Partnrs increased their Q1 2025 earnings estimates for Beam Therapeutics in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.20) per share for the quarter, up from their previous estimate of ($1.26). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics' Q2 2025 earnings at ($1.23) EPS, Q3 2025 earnings at ($1.22) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.89) EPS and FY2026 earnings at ($5.08) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.16. The firm had revenue of $30.00 million for the quarter, compared to analysts' expectations of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business's quarterly revenue was down 90.5% on a year-over-year basis. During the same quarter last year, the company posted $1.73 EPS.

A number of other equities analysts have also recently weighed in on the company. Jones Trading raised Beam Therapeutics from a "hold" rating to a "buy" rating and set a $34.00 price objective on the stock in a report on Monday, March 10th. Guggenheim restated a "buy" rating and issued a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research note on Monday, March 10th. Scotiabank upgraded shares of Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 target price on the stock in a research report on Monday, March 10th. Finally, Sanford C. Bernstein upgraded shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Beam Therapeutics currently has an average rating of "Buy" and a consensus price target of $50.82.

Remove Ads

Beam Therapeutics Price Performance

BEAM stock traded up $0.71 during mid-day trading on Thursday, hitting $24.01. 1,631,451 shares of the stock were exchanged, compared to its average volume of 1,221,550. The business has a fifty day moving average price of $26.76 and a 200 day moving average price of $25.93. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $35.25. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -13.64 and a beta of 1.91.

Insider Activity

In other news, CEO John M. Evans sold 30,000 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christine Bellon sold 1,241 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the completion of the transaction, the insider now directly owns 102,968 shares in the company, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.20% of the company's stock.

Institutional Investors Weigh In On Beam Therapeutics

Hedge funds have recently bought and sold shares of the business. Farallon Capital Management LLC raised its position in shares of Beam Therapeutics by 0.4% during the 4th quarter. Farallon Capital Management LLC now owns 8,239,123 shares of the company's stock valued at $204,330,000 after buying an additional 31,000 shares in the last quarter. ARK Investment Management LLC increased its stake in Beam Therapeutics by 8.2% during the fourth quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company's stock worth $175,287,000 after acquiring an additional 536,930 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Beam Therapeutics by 11.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company's stock valued at $98,149,000 after purchasing an additional 404,782 shares during the period. Nikko Asset Management Americas Inc. lifted its stake in shares of Beam Therapeutics by 11.4% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company's stock valued at $98,109,000 after purchasing an additional 404,782 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Beam Therapeutics by 12.5% in the 3rd quarter. State Street Corp now owns 3,929,557 shares of the company's stock worth $96,274,000 after purchasing an additional 437,402 shares during the period. Hedge funds and other institutional investors own 99.68% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.